Four novel octreotide analogs with cell-penetrating peptides (CPPs) at the N-terminus or C-terminus were synthesized by a stepwise Fmoc solid-phase synthesis strategy. The synthesized peptides were analyzed and characterized using reverse phase HPLC and MALDI-TOF mass spectrometry. The antiproliferative activity of the analogs was tested in vitro on human gastric (SGC-7901) and hepatocellular cancer (BEL7402) cell lines using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Interestingly, these analogs showed a higher anticancer activities than the parent octreotide except CMTPT03 analog. The results demonstrate that the designed octreotide analogs enhance their anticancer activity after linking together the CPPs to octreotide at the N-terminus, and are potential molecules for future use in cancer therapy and drug targeting.

Download full-text PDF

Source
http://dx.doi.org/10.1002/psc.1205DOI Listing

Publication Analysis

Top Keywords

octreotide analogs
12
octreotide
5
analogs
5
design synthesis
4
synthesis biological
4
biological activity
4
activity cell-penetrating
4
cell-penetrating peptide-modified
4
peptide-modified octreotide
4
analogs novel
4

Similar Publications

Involvement of ATF6 in Octreotide-Induced Endothelial Barrier Enhancement.

Pharmaceuticals (Basel)

November 2024

School of Basic Pharmaceutical and Toxicological Sciences, College of Pharmacy, University of Louisiana Monroe, Monroe, LA 71201, USA.

: Endothelial hyperpermeability is the hallmark of severe disease, including sepsis and acute respiratory syndrome (ARDS). The development of medical countermeasures to treat the corresponding illness is of utmost importance. Synthetic somatostatin analogs (SSA) are FDA-approved drugs prescribed in patients with neuroendocrine tumors, and they act via growth hormone (GH) suppression.

View Article and Find Full Text PDF

Small intestinal neuroendocrine tumors (SI-NETs) typically follow an indolent disease course and are often accompanied by mesenteric lymph node metastases upon diagnosis. These tumors can incite a fibroblastic reaction within the mesenteric root. Here, we present two cases of patients with symptomatic small bowel obstruction due to such mesenteric involvement.

View Article and Find Full Text PDF

Objectives: Triple negative breast cancer (TNBC) is a distinct subtype of breast cancer that has a poor prognosis due to the lack of effective therapeutic agents. Since a significant proportion of human surgical samples of TNBC expressed mRNA for the growth hormone (GH), growth hormone-releasing hormone (GHRH), and gonadotropin-releasing hormone (GnRH) receptors, and the mitogenic proliferative activity of GH, GHRH, and GnRH, have been identified as effective therapeutic targets for somatostatin and its analogs and GnRH analogs, Di Bella Method (DBM), a combination of hormonal analogs and vitamins, was introduced to target and inhibit solid tumors. The present study aimed to improve the prognosis of TNBC using DBM in women with TNBC.

View Article and Find Full Text PDF

Background: Somatostatin analogs (SSAs) binding to and activating somatostatin receptors (SSTRs) have been extensively used for the treatment of neuroendocrine tumors (NETs). The currently approved synthetic SSAs have high affinity for SSTR2 (octreotide/lanreotide), or for SSTR2 and SSTR5 (pasireotide). These agents have shown symptoms control and antiproliferative effects in subsets of NET patients and this was associated to the expression of the targeted SSTRs.

View Article and Find Full Text PDF

Gallium-68-DOTA-D-phe1-try3-octreotide (Ga-DOTATOC) positron emission tomography/computed tomography (PET/CT) is a crucial diagnostic tool for neuroendocrine tumors (NET). Its accuracy is influenced by radiochemical purity and patient preparation. We present two cases where unexpected radiotracer uptake in Ga-DOTATOC PET/CT imaging was observed.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!